AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22937265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 48
Study 22937265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine plus CBT
Number of subjects: 48
Study 22937265 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 48
Study 22937265 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine plus CBT
Number of subjects: 48
Study 19138379 — intervention group
Group type: EXPERIMENTAL
Intervention: NN1731 (5-30 microg kg(‐1))
Number of subjects: 8
Study 19138379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17656028 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based therapeutic intervention
Number of subjects: 117
Study 17656028 — intervention group
Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 117
Study 17656028 — intervention group
Group type: COMPARATOR
Intervention: Community comparison group (non-maltreated children)
Number of subjects: 117
Study 15522043 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cycle exercise test with respiratory gas analysis
Number of subjects: 25
Study 15522043 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and re-test on two consecutive days
Number of subjects: 25
Study 11748776 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram augmentation (20-40 mg/day)
Number of subjects: 19
Study 11748776 — intervention group
Group type: COMPARATOR
Intervention: No citalopram augmentation
Number of subjects: 19
Study 9023596 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD (420 kcal/d)
Number of subjects: 93
Study 9023596 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCD (530 kcal/d)
Number of subjects: 93
Study 9023596 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD (880 kcal/d)
Number of subjects: 93
Study 8343034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 15
Study 8343034 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 15
Study 8343034 — intervention group
Group type: COMPARATOR
Intervention: m-CPP (placebo)
Number of subjects: 15
Study 3717618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 2 mg phenylephrine
Number of subjects: 65
Study 3717618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 5 mg phenylephrine
Number of subjects: 65
Study 3717618 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (control group)
Number of subjects: 65
Study 30311902 — intervention group
Group type: EXPERIMENTAL
Intervention: As Is mud
Number of subjects: 75
Study 30311902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud with extra Dead Sea salt
Number of subjects: 75
Study 30311902 — intervention group
Group type: EXPERIMENTAL
Intervention: Over‐the‐shelf mud
Number of subjects: 75
Study 27905884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg t.i.d. for 3 days
Number of subjects: 322
Study 27905884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg b.i.d. for 5 days
Number of subjects: 322
Study 25286026 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR A.M. (GXR in the morning and placebo in the evening)
Number of subjects: 333
Study 25286026 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR P.M. (placebo in the morning and GXR in the evening)
Number of subjects: 333
Study 25286026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice-daily placebo)
Number of subjects: 333
Study 22790893 — intervention group
Group type: EXPERIMENTAL
Intervention: Corset wearing for 6 months (CW)
Number of subjects: 40
Study 22790893 — intervention group
Group type: COMPARATOR
Intervention: No corset wearing (NW)
Number of subjects: 40
Study 20221773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary cycling power before exercise (1,075 +/‐ 214 W)
Number of subjects: 10
Study 20221773 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion during exhaustive cycling exercise
Number of subjects: 10
Study 19001772 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d XOS for 8 weeks
Number of subjects: 26
Study 19001772 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 26
Study 15850081 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine PRBS (room air plus 5% CO2)
Number of subjects: 20
Study 15850081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt PRBS (room air plus 5% CO2)
Number of subjects: 20
Study 15850081 — intervention group
Group type: COMPARATOR
Intervention: Supine Control (room air)
Number of subjects: 20
Study 15850081 — intervention group
Group type: COMPARATOR
Intervention: Tilt Control (room air)
Number of subjects: 20
Study 12091259 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nutritional supplements (vitamins, minerals, essential fatty acids)
Number of subjects: 231
Study 12091259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 11934086 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood alcohol concentration (BAC)
Number of subjects: 0
Study 11934086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood alcohol concentration (BAC)
Number of subjects: 0
Study 11934086 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming alcohol concepts and trait-level NFC
Number of subjects: 0
Study 9527094 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion
Number of subjects: 10
Study 9527094 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin infusion
Number of subjects: 10
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A‐‐'10, 30‐13, 30' approach
Number of subjects: 250
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B‐‐the subpubic approach
Number of subjects: 250
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C‐‐subcutaneous ring block
Number of subjects: 250
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D‐‐a combination of frenulum infiltration and the '10, 30‐13, 30' approach
Number of subjects: 250
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E‐‐a combination of frenulum infiltration and the subpubic approach
Number of subjects: 250
Study 7867113 — intervention group
Group type: COMPARATOR
Intervention: Groups A, B, C, D, E
Number of subjects: 250
Study 7867113 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ring block or a combination of dorsal nerve block (using the '10, 30‐13, 30' or the subpubic approach) and infiltration of the frenulum
Number of subjects: 250
Study 2671200 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinburnin (45 mg iv per day)
Number of subjects: 40
Study 2671200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 991148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (CA) synchronization plus vincristine, prednisone, and L-asparaginase
Number of subjects: 0
Study 991148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CA synchronization)
Number of subjects: 0
Study 31270116 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps Towards Alcohol Misuse Prevention Programme (STAMPP)
Number of subjects: 105
Study 31270116 — intervention group
Group type: COMPARATOR
Intervention: Education as normal (EAN)
Number of subjects: 105
Study 27814667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Ankle Instability (CAI) group
Number of subjects: 63
Study 27814667 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 63
Study 25989482 — intervention group
Group type: EXPERIMENTAL
Intervention: Real LFTMS with TENS
Number of subjects: 0
Study 25989482 — intervention group
Group type: COMPARATOR
Intervention: Sham LFTMS with TENS
Number of subjects: 0
Study 25989482 — intervention group
Group type: EXPERIMENTAL
Intervention: LFTMS alone
Number of subjects: 0
Study 23106186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg(‐1)
Number of subjects: 80
Study 23106186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 μg.kg(‐1)
Number of subjects: 80
Study 23106186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23106186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 21767840 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbent pad A
Number of subjects: 17
Study 21767840 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbent pad B
Number of subjects: 17
Study 21767840 — intervention group
Group type: COMPARATOR
Intervention: Control condition (follicular phase)
Number of subjects: 17
Study 19361897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake <3 g/day (group 1)
Number of subjects: 49
Study 19361897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake >6 g/day (group 2)
Number of subjects: 49
Study 19361897 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 49
Study 17065975 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 17065975 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 15275792 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and a weak oral opioid or morphine (dose ≤90 mg/day)
Number of subjects: 60
Study 15275792 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and morphine (dose ≥90 mg/day)
Number of subjects: 60
Study 15275792 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy only (Control group)
Number of subjects: 60
Study 10675057 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat pan with radius of curvature 75 cm, back-rest with radius of curvature 30 cm, back-rest inclination of 10 degrees
Number of subjects: 0
Study 10675057 — intervention group
Group type: COMPARATOR
Intervention: Seat pans with radius of curvatures of 60, 75, 90 and infinity cm
Number of subjects: 0
Study 10675057 — intervention group
Group type: COMPARATOR
Intervention: Back-rests with radius of curvatures of 30, 60, 90 and infinity cm
Number of subjects: 0
Study 10675057 — intervention group
Group type: COMPARATOR
Intervention: Back-rest inclinations of 0 degrees, 5 degrees and 10 degrees
Number of subjects: 0
Study 9070471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg per kilogram of body weight, max 800 mg, given every six hours for eight doses)
Number of subjects: 455
Study 9070471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 9070471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 455
Study 8363997 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6)
Number of subjects: 160
Study 8363997 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron plus dexamethasone (Group B2)
Number of subjects: 160
Study 8363997 — intervention group
Group type: COMPARATOR
Intervention: tropisetron plus placebo (Group B1)
Number of subjects: 160
Study 31844890 — intervention group
Group type: EXPERIMENTAL
Intervention: VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 256
Study 31844890 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 256
Study 31844890 — intervention group
Group type: EXPERIMENTAL
Intervention: VB-111 and bevacizumab combination
Number of subjects: 256
Study 28258773 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg administered 1 hour before surgery
Number of subjects: 98
Study 28258773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25370526 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer purse-string uterine closure (Turan technique)
Number of subjects: 168
Study 25370526 — intervention group
Group type: COMPARATOR
Intervention: Classical double-layer uterine closure
Number of subjects: 168
Study 23204164 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 269
Study 23204164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF-emtricitabine (TDF/FTC)
Number of subjects: 269
Study 23204164 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ABC/3TC and TDF/FTC
Number of subjects: 269
Study 21458811 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week exercise program
Number of subjects: 50
Study 21458811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 19842230 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy plus surgery (CRTS)
Number of subjects: 1737
Study 19842230 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent neoadjuvant chemoradiotherapy
Number of subjects: 1737
Study 19842230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential neoadjuvant chemoradiotherapy
Number of subjects: 1737
Study 18021949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock panic attacks as an unconditioned stimulus (UCS)
Number of subjects: 59
Study 18021949 — intervention group
Group type: EXPERIMENTAL
Intervention: CS(+) (conditioned stimulus associated with panic)
Number of subjects: 59
Study 18021949 — intervention group
Group type: COMPARATOR
Intervention: CS(-) (conditioned stimulus not associated with panic)
Number of subjects: 59
Study 15349535 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic sheath technique in Indianapolis
Number of subjects: 109
Study 15349535 — intervention group
Group type: COMPARATOR
Intervention: Modified silastic sheath technique in London
Number of subjects: 109
Study 11570941 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of influenza
Number of subjects: 1033
Study 11570941 — intervention group
Group type: COMPARATOR
Intervention: Laboratory diagnostic techniques (viral isolation, hemagglutinin inhibition serology, multiplex reverse transcription polymerase chain reaction)
Number of subjects: 1033
Study 11570941 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1033
Study 11570941 — intervention group
Group type: EXPERIMENTAL
Intervention: Total symptom scores at baseline
Number of subjects: 1033
Study 9593030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9)
Number of subjects: 24
Study 9593030 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 24
Study 9593030 — intervention group
Group type: COMPARATOR
Intervention: Dextrin sulfate (D2S)
Number of subjects: 24
Study 7923516 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 80
Study 7923516 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.75 mg.kg‐1
Number of subjects: 80
Study 7923516 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 1 mg.kg‐1
Number of subjects: 80
Study 7923516 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg.kg‐1 (Control)
Number of subjects: 80
Study 3407900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intubation with a laryngoscope (Group A, n = 50)
Number of subjects: 140
Study 3407900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation using a fiberoptic endoscope (Group B, n = 40)
Number of subjects: 140
Study 3407900 — intervention group
Group type: COMPARATOR
Intervention: Face mask (Group C, n = 50)
Number of subjects: 140
Study 29514121 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive interpersonal beliefs measured by the Interpersonal Needs Questionnaire (INQ)
Number of subjects: 101
Study 29514121 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition accuracy (Penn ER‐40)
Number of subjects: 101
Study 29514121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias toward perceiving anger in neutral expressions
Number of subjects: 101
Study 29514121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive ability adjustment
Number of subjects: 101
Study 29514121 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia vs. bipolar disorder
Number of subjects: 101
Study 28579406 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-all policy
Number of subjects: 171
Study 26331956 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal rich in polyunsaturated fatty acids (PUFAs)
Number of subjects: 16
Study 26331956 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal rich in monounsaturated fatty acids (MUFAs)
Number of subjects: 16
Study 26331956 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal rich in saturated fatty acids (SFAs)
Number of subjects: 16
Study 23964826 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Glamorgan Scale (mGS)
Number of subjects: 112
Study 23964826 — intervention group
Group type: COMPARATOR
Intervention: Glamorgan Scale (GS)
Number of subjects: 112
Study 20100734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-dialytic low-intensity strength training
Number of subjects: 50
Study 20100734 — intervention group
Group type: COMPARATOR
Intervention: Stretching (attention-control) exercises
Number of subjects: 50
Study 18251642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy delivered for 20 minutes using a piezoelectric transducer for 10 sessions over 4 weeks.
Number of subjects: 12
Study 18251642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 12
Study 18251642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound therapy)
Number of subjects: 12
Study 17034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg via Turbuhaler
Number of subjects: 176
Study 17034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg (metered dose inhaler)
Number of subjects: 176
Study 17034311 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 6 microg via Turbuhaler
Number of subjects: 176
Study 17034311 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 176
Study 14605789 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline chitosan (MCC) 1.2 g twice daily
Number of subjects: 130
Study 14605789 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1.2 g twice daily
Number of subjects: 130
Study 11128753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral reduction mammaplasty
Number of subjects: 69
Study 11128753 — intervention group
Group type: COMPARATOR
Intervention: Preoperative state
Number of subjects: 69
Study 11128753 — intervention group
Group type: COMPARATOR
Intervention: Nonpatient control groups
Number of subjects: 69
Study 9232667 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiphenesin and bromhexine
Number of subjects: 0
Study 9232667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 mg single dose)
Number of subjects: 0
Study 9232667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1596352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air loss bed (Mediscus)
Number of subjects: 20
Study 1596352 — intervention group
Group type: COMPARATOR
Intervention: Foam mattress with loose-fitting top cover (Comfortex)
Number of subjects: 20
Study 2982694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein diet supplemented with psyllium fiber (0.8 g/kg body wt, 1800 kcal/day)
Number of subjects: 8
Study 2982694 — intervention group
Group type: COMPARATOR
Intervention: Meat protein diet (0.8 g/kg body wt, approximately 1800 kcal/day) plus neomycin and laxatives
Number of subjects: 8
Study 2982694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein diet plus fiber
Number of subjects: 8
Study 31093740 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2324
Study 27613912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nicotine replacement therapy (NRT) and behavioral counseling
Number of subjects: 269
Study 27613912 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-abstainers)
Number of subjects: 269
Study 26845524 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS
Number of subjects: 35
Study 26845524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal 2-mA tDCS
Number of subjects: 35
Study 26845524 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 35
Study 25033113 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive processing therapy (CPT)
Number of subjects: 0
Study 25033113 — intervention group
Group type: COMPARATOR
Intervention: Individual support
Number of subjects: 0
Study 22399366 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic dilation (TID)
Number of subjects: 547
Study 22399366 — intervention group
Group type: EXPERIMENTAL
Intervention: TID combined with mild to moderate perfusion abnormality (3% ≤ TPD < 10%)
Number of subjects: 547
Study 22399366 — intervention group
Group type: EXPERIMENTAL
Intervention: TID(ed)/TID(es)
Number of subjects: 547
Study 22399366 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke prognostic CAD index (DI)
Number of subjects: 547
Study 19155521 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 L1 VLP vaccine
Number of subjects: 21
Study 17969818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (short‐acting insulin in each meal and medium‐acting insulin before going to bed)
Number of subjects: 42
Study 17969818 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (two doses: morning and evening)
Number of subjects: 42
Study 17969818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 42
Study 15558090 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight 'F' speed film (right side)
Number of subjects: 12
Study 15558090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐Speed 'D' film (left side)
Number of subjects: 12
Study 15558090 — intervention group
Group type: COMPARATOR
Intervention: Insight Film (control, both sides)
Number of subjects: 12
Study 11402107 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 44 microg
Number of subjects: 618
Study 11402107 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a 22 microg
Number of subjects: 618
Study 11402107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 9402173 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU + MMC
Number of subjects: 200